Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
äŒæ¥ã³ãŒãANIK
äŒç€ŸåAnika Therapeutics Inc
äžå Žæ¥May 16, 1985
æé«çµå¶è²¬ä»»è
ãCEOãBlanchard (Cheryl Renee)
åŸæ¥å¡æ°288
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«May 16
æ¬ç€Ÿæåšå°32 Wiggins Ave
éœåžBEDFORD
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·01730-2315
é»è©±çªå·17814579000
ãŠã§ããµã€ãhttps://anika.com/
äŒæ¥ã³ãŒãANIK
äžå Žæ¥May 16, 1985
æé«çµå¶è²¬ä»»è
ãCEOãBlanchard (Cheryl Renee)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã